With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

Nucala (mepolizumab) is a prescription drug used to treat a severe type of asthma and certain other inflammatory conditions. Nucala comes as an injection that you give under your skin. Nucala ...

A real-life study suggests that stepping down mepolizumab dosage in EGPA patients in remission is effective, with no asthma ...

Results of the study showed that 51.1% of benralizumab-treated patients compared with 45.4% of mepolizumab-treated patients attained a complete or partial response at 3 months. Notably, the complete ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD ...

GSK plc announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), ...

1. Why am I being given NUCALA? NUCALA contains the active ingredient mepolizumab. NUCALA is used to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) with an ...